PTC THERAPEUTICS, INC. 4

CFO Pierre Gravier sold 3,494 shares of PTC Therapeutics common stock at $80.35 per share in an automatic sell-to-cover transaction tied to RSU vesting.

On July 14, 2026, PTC Therapeutics, Inc. Chief Financial Officer Pierre Gravier executed an automatic sale of 3,494 shares of common stock at an average price of $80.35 per share, totaling approximately $280,800, to cover tax withholding obligations arising from the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs. The transaction was effected pursuant to an irrevocable sell-to-cover election made at the time of grant acceptance and is characterized as a routine tax-related sale rather than a discretionary open-market disposition. Following the transaction, Gravier directly owned 83,986 shares of PTC Therapeutics common stock, which includes 162 shares acquired through the company’s employee stock purchase plan for the period ended June 30, 2026.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001984065-26-000008

Alert Tier

5